Literature DB >> 32929642

Detection of gadolinium deposition in cortical bone with ultrashort echo time T1 mapping: an ex vivo study in a rabbit model.

Kaixuan Zhao1,2, Shisi Li3, Peiwei Yi1,2, Yihao Guo1,2, Qinqin Yu3, Cuiling Zhu3, Qianjin Feng1,2, Jiang Du4, Xiaodong Zhang5, Yanqiu Feng6,7.   

Abstract

OBJECTIVES: To investigate the capacity of ultrashort echo time (UTE) T1 mapping to non-invasively assess gadolinium deposition in cortical bone after gadolinium-based contrast agent (GBCA) administration.
METHODS: Twenty-eight New Zealand rabbits (male, 3.0-3.5 kg) were randomly allocated into control, macrocyclic, high-dose macrocyclic, and linear GBCA groups (n = 7 for each group), and respectively given daily doses of 0.9 ml/kg bodyweight saline, 0.3 mmol/kg bodyweight gadobutrol, 0.9 mmol/kg bodyweight gadobutrol, and 0.3 mmol/kg bodyweight gadopentetate dimeglumine for five consecutive days per week over a period of 4 weeks. After a subsequent 4 weeks of recovery, the rabbits were sacrificed and their tibiae harvested. T1 value of cortical bone was measured using a combination of UTE actual flip angle imaging and variable repetition time on a 7T animal scanner. Gadolinium concentration in cortical bone was measured using inductively coupled plasma mass spectrometry (ICP-MS). Pearson's correlation between R1 value (R1 = 1/T1) and gadolinium concentration in cortical bone was assessed.
RESULTS: Bone T1 values were significantly lower in the lower-dose macrocyclic (329.2 ± 21.0 ms, p < 0.05), higher-dose macrocyclic (316.8 ± 21.7 ms, p < 0.01), and linear (296.8 ± 24.1 ms, p < 0.001) GBCA groups compared with the control group (356.3 ± 19.4 ms). Gadolinium concentrations measured by ICP-MS in the control, lower-dose macrocyclic, higher-dose macrocyclic, and linear GBCA groups were 0.04 ± 0.02 μg/g, 2.60 ± 0.48 μg/g, 4.95 ± 1.17 μg/g, and 13.62 ± 1.55 μg/g, respectively. There was a strong positive correlation between R1 values and gadolinium concentrations in cortical bone (r = 0.73, p < 0.001).
CONCLUSIONS: These results suggest that UTE T1 mapping has the potential to provide a non-invasive assessment of gadolinium deposition in cortical bone following GBCA administration. KEY POINTS: • Changes in T1 value related to gadolinium deposition were found in bone after both linear and macrocyclic GBCA administrations. • R1 relaxometry correlates strongly with gadolinium concentration in cortical bone. • UTE T1 mapping provides a potential tool for non-invasively monitoring gadolinium deposition in cortical bone.

Entities:  

Keywords:  Contrast media; Cortical bone; Gadolinium; Magnetic resonance imaging

Mesh:

Substances:

Year:  2020        PMID: 32929642     DOI: 10.1007/s00330-020-07258-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  42 in total

Review 1.  Bone as target organ for metals: the case of f-elements.

Authors:  Claude Vidaud; Damien Bourgeois; Daniel Meyer
Journal:  Chem Res Toxicol       Date:  2012-04-22       Impact factor: 3.739

2.  Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.

Authors:  A Luana Stanescu; Dennis W Shaw; Nozomu Murata; Kiyoko Murata; Joe C Rutledge; Ezekiel Maloney; Kenneth R Maravilla
Journal:  Pediatr Radiol       Date:  2020-01-27

3.  High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration.

Authors:  Tomonori Kanda; Marie Osawa; Hiroshi Oba; Keiko Toyoda; Jun'ichi Kotoku; Takahiro Haruyama; Koji Takeshita; Shigeru Furui
Journal:  Radiology       Date:  2015-01-27       Impact factor: 11.105

4.  Non-clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance®) to neonatal and juvenile rats.

Authors:  Simona Bussi; Laure Penard; Roberta Bonafè; Catherine Botteron; Roberto Celeste; Alessandra Coppo; Roberta Queliti; Miles A Kirchin; Fabio Tedoldi; Federico Maisano
Journal:  Regul Toxicol Pharmacol       Date:  2017-12-24       Impact factor: 3.271

5.  Self-reported gadolinium toxicity: A survey of patients with chronic symptoms.

Authors:  Lauren M B Burke; Miguel Ramalho; Mamdoh AlObaidy; Emily Chang; Michael Jay; Richard C Semelka
Journal:  Magn Reson Imaging       Date:  2016-05-19       Impact factor: 2.546

6.  Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.

Authors:  Nozomu Murata; Luis F Gonzalez-Cuyar; Kiyoko Murata; Corinne Fligner; Russell Dills; Daniel Hippe; Kenneth R Maravilla
Journal:  Invest Radiol       Date:  2016-07       Impact factor: 6.016

7.  Incorporation of excess gadolinium into human bone from medical contrast agents.

Authors:  Thomas H Darrah; Jennifer J Prutsman-Pfeiffer; Robert J Poreda; M Ellen Campbell; Peter V Hauschka; Robyn E Hannigan
Journal:  Metallomics       Date:  2009-09-16       Impact factor: 4.526

Review 8.  Exposure, metabolism, and toxicity of rare earths and related compounds.

Authors:  S Hirano; K T Suzuki
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

9.  Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats.

Authors:  Simona Bussi; Alessandra Coppo; Catherine Botteron; Valérie Fraimbault; Antonello Fanizzi; Elisa De Laurentiis; Sonia Colombo Serra; Miles A Kirchin; Fabio Tedoldi; Federico Maisano
Journal:  J Magn Reson Imaging       Date:  2017-07-21       Impact factor: 4.813

Review 10.  25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives.

Authors:  Jessica Lohrke; Thomas Frenzel; Jan Endrikat; Filipe Caseiro Alves; Thomas M Grist; Meng Law; Jeong Min Lee; Tim Leiner; Kun-Cheng Li; Konstantin Nikolaou; Martin R Prince; Hans H Schild; Jeffrey C Weinreb; Kohki Yoshikawa; Hubertus Pietsch
Journal:  Adv Ther       Date:  2016-01-25       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.